Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03236935
Title Phase Ib of L-NMMA and Pembrolizumab
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Jorge G. Darcourt
Indications

transitional cell carcinoma

head and neck squamous cell carcinoma

lung non-small cell carcinoma

melanoma

Hodgkin's lymphoma

Advanced Solid Tumor

Therapies

L-NMMA + Pembrolizumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.